Tumor evasion of humoral immunity mediated by proteolytic impairment of antibody triggered immune effector function.

Abstract:

:Immune suppression is recognized as a hallmark of cancer and this notion is largely based on studies on cellular immunity. Our recent studies have demonstrated a potential new mechanism of cancer suppression of immunity by impairment of antibody effector function mediated by proteolytic enzymes in the tumor microenvironment.

journal_name

Oncoimmunology

journal_title

Oncoimmunology

authors

Zhang N,Jordan RE,An Z

doi

10.1080/2162402X.2015.1122861

subject

Has Abstract

pub_date

2015-12-29 00:00:00

pages

e1122861

issue

5

eissn

2162-4011

issn

2162-402X

pii

1122861

journal_volume

5

pub_type

杂志文章
  • Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies.

    abstract::We have developed a highly versatile platform for the systematic retrieval of T-cell receptors (TCRs) from single-antigen-reactive T cells and for characterization of their function and specificity. This approach enables rapid extraction of multiple TCRs from repertoires in individuals and not only broadens the divers...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1005523

    authors: Omokoko T,Simon P,Türeci Ö,Sahin U

    更新日期:2015-03-19 00:00:00

  • Development and validation of an immune-related gene pairs signature in colorectal cancer.

    abstract::Although the outcome of colorectal cancer (CRC) patients has improved significantly with the recent implementation of annual screening programs, reliable prognostic biomarkers are still needed due to the disease heterogeneity. Increasing pieces of evidence revealed an association between immune signature and CRC progn...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2019.1596715

    authors: Wu J,Zhao Y,Zhang J,Wu Q,Wang W

    更新日期:2019-04-15 00:00:00

  • Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients.

    abstract::We have developed a recombinant adenovirus vaccine encoding dopachrome tautomerase (rHuAd5-hDCT) that produces robust DCT-specific immunity, but only provides modest suppression of murine melanoma. In the current study, an agonist antibody against 4-1BB was shown to enhance rHuAd5-hDCT efficacy and evoke tumor regress...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.19534

    authors: McGray AJ,Bernard D,Hallett R,Kelly R,Jha M,Gregory C,Bassett JD,Hassell JA,Pare G,Wan Y,Bramson JL

    更新日期:2012-07-01 00:00:00

  • Tumor-induced neutrophil extracellular traps-drivers of systemic inflammation and vascular dysfunction.

    abstract::Neutrophil extracellular traps (NETs) are part of the innate immune defense against microbes, but their contribution to several non-infectious inflammatory conditions has recently been unraveled. We demonstrate that NETs accumulate in the peripheral circulation in tumor-bearing mice, causing systemic inflammation and ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1098803

    authors: Cedervall J,Dimberg A,Olsson AK

    更新日期:2015-10-29 00:00:00

  • A novel immunization strategy using cytokine/chemokines induces new effective systemic immune responses, and frequent complete regressions of human metastatic melanoma.

    abstract::Immune responses have been elicited by a variety of cancer vaccines, but seldom induce regressions of established cancers in humans. As a novel therapeutic immunization strategy, we tested the hypothesis that multiple cytokines/chemokines secreted early in secondary responses ex-vivo might mimic the secretory environm...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1386827

    authors: Valentine FT,Golomb FM,Harris M,Roses DF

    更新日期:2017-10-30 00:00:00

  • Peripheral trafficking of bone-marrow-derived stem cells in patients with different types of gastric neoplasms.

    abstract::Recently, there has been a growing interest in the importance of stem cells (SCs) in the development/progression of gastric neoplasms. In this study, we performed a comprehensive analysis of different populations of bone-marrow-derived stem cells (BMSCs) in patients with various types of gastric malignancies, includin...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1099798

    authors: Błogowski W,Zuba-Surma E,Sałata D,Budkowska M,Dołęgowska B,Starzyńska T

    更新日期:2015-10-29 00:00:00

  • Why do human B cells secrete granzyme B? Insights into a novel B-cell differentiation pathway.

    abstract::B cells are generally believed to operate as producers of high affinity antibodies to defend the body against microorganisms, whereas cellular cytotoxicity is considered as an exclusive prerogative of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). In conflict with this dogma, recent studies have demonst...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.22354

    authors: Hagn M,Jahrsdörfer B

    更新日期:2012-11-01 00:00:00

  • The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.

    abstract::Analysis of PDL1 mRNA expression in ∼5,500 breast cancers showed PDL1 upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1085148

    authors: Bertucci F,Finetti P,Birnbaum D,Mamessier E

    更新日期:2015-08-31 00:00:00

  • Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors.

    abstract::Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to pr...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2015.1122158

    authors: Tsai AK,Davila E

    更新日期:2016-01-15 00:00:00

  • Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.

    abstract::Merkel cell carcinoma (MCC) is a rare skin cancer caused by Merkel cell polyomavirus (MCPyV) infection and/or ultraviolet radiation-induced somatic mutations. The presence of tumor-infiltrating lymphocytes is evidence that an active immune response to MCPyV and tumor-associated neoantigens occurs in some patients. How...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2017.1338237

    authors: Schadendorf D,Nghiem P,Bhatia S,Hauschild A,Saiag P,Mahnke L,Hariharan S,Kaufman HL

    更新日期:2017-08-31 00:00:00

  • The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.

    abstract::Tumor-associated macrophages (TAM) are immunosuppressive cells that can massively accumulate in the tumor microenvironment. In patients with ovarian cancer, their density is correlated with poor prognosis. Targeting mediators that control the generation or the differentiation of immunoregulatory macrophages represents...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1178025

    authors: d'Almeida SM,Kauffenstein G,Roy C,Basset L,Papargyris L,Henrion D,Catros V,Ifrah N,Descamps P,Croue A,Jeannin P,Grégoire M,Delneste Y,Tabiasco J

    更新日期:2016-04-28 00:00:00

  • Rehmannia glutinosa polysaccharide induces toll-like receptor 4 dependent spleen dendritic cell maturation and anti-cancer immunity.

    abstract::Rehmannia glutinosa polysaccharide (RGP) has shown an activation of immune cells in vitro. However, the immune stimulatory effect of RGP in a mouse in vivo is not well studied. In this study, we examined the effect of RGP on dendritic cell (DC) activation and anticancer immunity in vivo. Treatments of RGP in C56BL/6 m...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1325981

    authors: Xu L,Kwak M,Zhang W,Zeng L,Lee PC,Jin JO

    更新日期:2017-05-12 00:00:00

  • Mammaglobin-A is a target for breast cancer vaccination.

    abstract::We recently completed a phase 1 clinical trial demonstrating the safety of a mammaglobin-A DNA vaccine in patients with metastatic breast cancer. We are currently enrolling patients with early stage breast cancer in a phase 1b clinical trial. The mammaglobin-A DNA vaccine will be administered concurrently with neoadju...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1069940

    authors: Kim SW,Goedegebuure P,Gillanders WE

    更新日期:2016-02-26 00:00:00

  • Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1.

    abstract::Human pancreatic ductal adenocarcinoma (PDAC) exhibits marginal responses to anti-PD-1/PD-L1 immunotherapy and its mechanism remains poorly understood. We have investigated the effect of anti-PD-L1 and c-Myc inhibition in PDAC. Using 87 patients with PDAC from our hospital database we found a significant correlation b...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2019.1581529

    authors: Pan Y,Fei Q,Xiong P,Yang J,Zhang Z,Lin X,Pan M,Lu F,Huang H

    更新日期:2019-03-01 00:00:00

  • Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor.

    abstract::Due to their constant exposure to inhaled antigens, lungs represent a particularly immunosuppressive environment that limits excessive immune responses; however, cancer cells can exploit this unique environment for their growth. We previously described the ability of aerosolized CpG-ODN combined with Poly(I:C) (TLR9 a...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1234571

    authors: Le Noci V,Sommariva M,Tortoreto M,Zaffaroni N,Campiglio M,Tagliabue E,Balsari A,Sfondrini L

    更新日期:2016-09-20 00:00:00

  • Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome.

    abstract::Epithelial Ovarian cancer (EOC) is the most lethal gynecological malignancy and has limited curative therapeutic options. Immunotherapy for EOC is promising, but clinical efficacy remains restricted to a small percentage of patients. Several lines of evidence suggest that the low response rate might be improved by com...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1760705

    authors: Brunekreeft KL,Paijens ST,Wouters MCA,Komdeur FL,Eggink FA,Lubbers JM,Workel HH,Van Der Slikke EC,Pröpper NEJ,Leffers N,Adam J,Pijper H,Plat A,Kol A,Nijman HW,De Bruyn M

    更新日期:2020-05-13 00:00:00

  • Fusions between dendritic cells and whole tumor cells as anticancer vaccines.

    abstract::Various strategies have been developed to deliver tumor-associated antigens (TAAs) to dendritic cells (DCs). Among these, the fusion of DCs and whole cancer cells can process a broad array of TAAs, including hitherto unidentified molecules, and present them in complex with MHC Class I and II molecules and in the conte...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.24437

    authors: Koido S,Homma S,Okamoto M,Namiki Y,Takakura K,Uchiyama K,Kajihara M,Arihiro S,Imazu H,Arakawa H,Kan S,Komita H,Ito M,Ohkusa T,Gong J,Tajiri H

    更新日期:2013-05-01 00:00:00

  • The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy.

    abstract::Renal cell carcinoma (RCC) is an immunogenic tumor, but uses several immune-suppressive mechanisms to shift the balance from tumor immune response toward tumor growth. Although RCC has traditionally been considered to be radiation resistant, recent evidence suggests that hypofractionated radiotherapy contributes to sy...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2015.1042198

    authors: De Wolf K,Vermaelen K,De Meerleer G,Lambrecht BN,Ost P

    更新日期:2015-05-27 00:00:00

  • High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes.

    abstract::The presence of tumor-infiltrating lymphocytes (TILs) is a strong prognostic parameter for local dissemination and overall survival in melanoma. Lymphocyte migration from blood into peripheral tissues is mainly regulated by vascular endothelium. However, the blood vessels and mechanisms governing the recruitment of TI...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.20492

    authors: Martinet L,Le Guellec S,Filleron T,Lamant L,Meyer N,Rochaix P,Garrido I,Girard JP

    更新日期:2012-09-01 00:00:00

  • High sensitivity of cancer exome-based CD8 T cell neo-antigen identification.

    abstract::Recent data suggest that T-cell reactivity against tumor-specific neo-antigens may be central to the clinical efficacy of cancer immunotherapy. The development of personalized vaccines designed to boost T-cell reactivity against patient specific neo-antigens has been proposed largely on the basis of these findings. Wo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.28836

    authors: van Buuren MM,Calis JJ,Schumacher TN

    更新日期:2014-05-14 00:00:00

  • Autochthonous T cells to the rescue: IL-10 directly activates tumor-resident CD8(+) T cells.

    abstract::Successful cancer immunotherapy is thought to require de novo priming of tumor specific CD8(+) T cells in lymphatic organs. Contrasting these beliefs, cancer therapy based on interleukin-10 (IL-10) results in tumor rejection without a requirement for T-cell trafficking from lymphatic organs. Rather, IL-10 directly act...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.21683

    authors: Emmerich J,Mumm JB,Oft M

    更新日期:2012-12-01 00:00:00

  • Trial Watch: Peptide vaccines in cancer therapy.

    abstract::Throughout the past 3 decades, along with the recognition that the immune system not only influences oncogenesis and tumor progression, but also determines how established neoplastic lesions respond therapy, renovated enthusiasm has gathered around the possibility of using vaccines as anticancer agents. Such an enthus...

    journal_title:Oncoimmunology

    pub_type: 评审

    doi:10.4161/onci.26621

    authors: Aranda F,Vacchelli E,Eggermont A,Galon J,Sautès-Fridman C,Tartour E,Zitvogel L,Kroemer G,Galluzzi L

    更新日期:2013-12-01 00:00:00

  • A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.

    abstract::Vaccines in combination with chemotherapy have been shown to be safe in different tumor types. We investigated the immunological activity of the TroVax® vaccine in combination with pemetrexed-cisplatin chemotherapy in malignant pleural mesothelioma (MPM). In this first line, open-label, single-arm, phase 2 study, pati...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1457597

    authors: Lester JF,Casbard AC,Al-Taei S,Harrop R,Katona L,Attanoos RL,Tabi Z,Griffiths GO

    更新日期:2018-09-07 00:00:00

  • Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.

    abstract::Gliomas are lethal brain tumors that resist standard therapeutic approaches. Immunotherapy is a promising alternative strategy mostly developed in the context of glioblastoma. However, there is a need for implementing immunotherapy for grade II/III gliomas, as these are the most common CNS tumors in young adults with ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1391972

    authors: Dutoit V,Migliorini D,Ranzanici G,Marinari E,Widmer V,Lobrinus JA,Momjian S,Costello J,Walker PR,Okada H,Weinschenk T,Herold-Mende C,Dietrich PY

    更新日期:2017-11-07 00:00:00

  • Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma.

    abstract::This proof-of-concept single-arm open-label phase I clinical trial (NCT02481934) studied the safety and efficacy of multiple infusions of activated and expanded natural killer (NKAE) cells in combination with anti-myeloma drugs in multiple myeloma patients. It included five patients with relapsed or refractory MM who ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1250051

    authors: Leivas A,Perez-Martinez A,Blanchard MJ,Martín-Clavero E,Fernández L,Lahuerta JJ,Martinez-Lopez J

    更新日期:2016-11-22 00:00:00

  • Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.

    abstract::Cutaneous angiosarcoma (CAS) is a malignant sarcoma with poor prognosis. Programmed cell death-1 (PD-1)/programmed cell death-1 ligand-1 (PD-L1) expression reflects antitumor immunity, and is associated with patient prognosis in various cancers. The purpose of this study is to investigate the relationship between PD-1...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1253657

    authors: Honda Y,Otsuka A,Ono S,Yamamoto Y,Seidel JA,Morita S,Hirata M,Kataoka TR,Takenouchi T,Fujii K,Kanekura T,Okubo Y,Takahashi K,Yanagi T,Hoshina D,Hata H,Abe R,Fujimura T,Funakoshi T,Yoshino K,Masuzawa M,Amoh Y,T

    更新日期:2016-11-04 00:00:00

  • Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models.

    abstract::In combination cancer immunotherapies, consideration should be given to designing treatment schedules that harmonize with the immune system's natural timing. An efficacious temporally programmed combination therapy of extended half-life interleukin 2 (eIL2), tumor targeting antibody, and interferon (IFN) α was recentl...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1558678

    authors: Rothschilds A,Tzeng A,Mehta NK,Moynihan KD,Irvine DJ,Wittrup KD

    更新日期:2019-02-19 00:00:00

  • A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.

    abstract::Preclinical data suggest that a "prime-boost" vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; however, this strategy has not been evaluated in a clinical setting. CMB305 is a prime-boost vaccine designed to induce a broa...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1847846

    authors: Somaiah N,Chawla SP,Block MS,Morris JC,Do K,Kim JW,Druta M,Sankhala KK,Hwu P,Jones RL,Gnjatic S,Kim-Schulze S,Tuballes K,Yishak M,Lu H,Yakovich A,Ter Meulen J,Chen M,Kenney RT,Bohac C,Pollack SM

    更新日期:2020-11-19 00:00:00

  • Egfl7 promotes tumor escape from immunity.

    abstract::Egfl7 is an endothelial-specific gene which expression is deregulated in human cancers. We showed that Egfl7 promotes tumor escape from immunity by downregulating the expression of leukocyte adhesion molecules in endothelial cells, thus repressing immune cell extravasation into tumors. ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.18964

    authors: Pinte S,Soncin F

    更新日期:2012-05-01 00:00:00

  • Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia.

    abstract::Graft-versus-host disease (GvHD) remains a significant impediment to allogeneic hematopoietic cell transplantation (HCT) success, necessitating studies focused on alleviating GvHD, while preserving the graft-versus-leukemia (GvL) effect. Based on our previous studies showing bendamustine with total body irradiation (B...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1758011

    authors: Stokes J,Hoffman EA,Molina MS,Kummet N,Simpson RJ,Zeng Y,Katsanis E

    更新日期:2020-04-30 00:00:00